PCSK9 and diabetes mellitus: This was an important objective, given previous observations that statins increase the risk of incident diabetes,38,39 and findings in Mendelian randomization analyses that genes encoding variants in PCSK9 associated with lower LDL-C levels are also associated with greater incident diabetes.40 In fact, alirocumab did not increase the risk of new-onset diabetes (Figure 1A) among patients without diabetes at baseline (including those with prediabetes).